Tirzepatide for Pediatric Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of tirzepatide, a new treatment for children aged 6 to under 12 who struggle with obesity. The goal is to determine if adding this medication to a healthy lifestyle can help children lose weight more effectively and safely. Participants will receive either tirzepatide or a placebo while continuing lifestyle changes like diet and exercise. Children who have previously attempted weight loss through structured programs without success might be a good fit for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.
Is there any evidence suggesting that tirzepatide is likely to be safe for children with obesity?
Research has shown that tirzepatide, a drug under study for childhood obesity, was generally well-tolerated in past trials. While the drug aids in reducing body weight, some participants experienced stomach-related issues like nausea and vomiting. These side effects are the most common and usually short-lived.
Trials with teenagers noted similar side effects, but the benefits, such as significant weight loss, were impressive. Ongoing studies aim to ensure the treatment's safety and effectiveness for younger people. Overall, evidence suggests that tirzepatide could be a promising option for managing weight, with manageable side effects.12345Why do researchers think this study treatment might be promising for obesity?
Tirzepatide is unique because it targets both the GLP-1 and GIP receptors, which play important roles in regulating hunger and energy balance. Most existing treatments for pediatric obesity, like lifestyle changes and medications such as orlistat, primarily focus on reducing calorie absorption or altering diet and exercise habits. Tirzepatide’s dual action could potentially result in more effective weight management by not only curbing appetite but also improving how the body processes sugar and fat. Researchers are excited about its potential to offer a more comprehensive approach to managing obesity in young people.
What evidence suggests that tirzepatide might be an effective treatment for pediatric obesity?
Research has shown that tirzepatide may help treat obesity. In earlier studies with adults, participants who took tirzepatide lost more weight than those who did not take the drug or who took other similar medications. Tirzepatide imitates hormones that control appetite and blood sugar, leading to reduced hunger and lower calorie intake. In this trial, participants will receive either tirzepatide or a placebo. Early results suggest that tirzepatide might also be effective for children with obesity, based on its mechanism and the results observed in adults.678910
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for children ages 6 to under 12 who have obesity. Participants should be generally healthy aside from their weight and able to follow a healthy lifestyle program during the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tirzepatide or placebo subcutaneously once weekly for 100 weeks, alongside a healthy lifestyle intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants may opt into an additional 156 weeks of treatment with tirzepatide and continue the lifestyle intervention
What Are the Treatments Tested in This Trial?
Interventions
- Tirzepatide
Trial Overview
The study compares a once-weekly injection of tirzepatide with a placebo, both combined with healthy lifestyle changes, over about two years. Some participants may continue tirzepatide for up to three more years after the main phase.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive tirzepatide subcutaneously (SC)
Participants will receive placebo SC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University
Citations
Data.gov Home - Data.gov
Here you will find data, tools, and resources to conduct research, develop web and mobile applications, design data visualizations, and more.
Data
Data is a collection of discrete or continuous values that conveys information, describing the quantity, quality, fact, statistics, other basic units of ...
data.org - Data and AI for mission
data.org coordinates across sectors to support and advance visionary—yet practical—solutions to drive impact through data and AI.
Data | An Open Access Journal from MDPI
Data is a peer-reviewed, open access journal on data in science, Median age was 64 years … median LDL-C decreased from 60 to 48 mg/dL,
DATA Definition & Meaning
The meaning of DATA is factual information (such as measurements or statistics) used as a basis for reasoning, discussion, or calculation.
can a 17 year old take tirzepatide for weight loss
Pediatric trial results for tirzepatide showed similar patterns: significant BMI reduction in the 12–17 age group, GI side
GLP-1 receptor agonists for the treatment of obesity in ...
GLP-1 agonists significantly decreased body weight. Gastrointestinal symptoms were the most frequent adverse event. GLP-1 receptor agonists ...
8.
xtalks.com
xtalks.com/tirzepatide-obesity-drug-shown-to-reduce-body-weight-by-20-percent-in-eli-lilly-trial-3059/Tirzepatide Obesity Drug Shown to Reduce Body Weight ...
people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo.
Tirzepatide Lowers Weight Across All Groups With Obesity
At 72 weeks, patients taking 5, 10, and 15 mg/week tirzepatide lost 21.5%, 20.8%, and 22% of their initial body weight, respectively.
Joints, Weight, and Mental Health: Ixekizumab + Tirzepatide for ...
The composite primary endpoint — simultaneous achievement of ACR50 and ≥10% weight reduction at week 36 — was met by 31.7% of patients on ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.